Ocrevus™ (Ocrelizumab) Phase III Trial Results Published

The results from three Phase III studies of the experimental medication Ocrevus™ (ocrelizumab) were published in the December 21, 2016 online issue of the New England Journal of Medicine (NEJM). Although initial findings had been presented at the 2015 ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) Annual Meeting and other MS conferences, […]

Read News Article

FDA Extends Review of Ocrevus™ (ocrelizumab)

On December 20, 2016, Genentech, a member of the Roche group, announced that the United States Food and Drug Administration (FDA) had extended the review period of Ocrevus™ (ocrelizumab) for the treatment of relapsing forms of MS (RMS) and primary-progressive MS (PPMS). This extension was needed to allow more time for the FDA to review […]

Read News Article

Highlights from the 2016 ECTRIMS Annual Meeting

More than 9,000 clinicians and researchers attended the 2016 meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in London, England. This year’s conference took place from September 14-17. The meeting was full of ground-breaking studies that promise to continue to advance the field toward better treatments for individuals with multiple […]

Read News Article

Make Your Voice Heard on MS Treatment

The Institute for Clinical and Economic Review (ICER) is currently conducting a review of disease-modifying therapies for relapsing-remitting and primary-progressive forms of multiple sclerosis. Insurers may use ICER recommendations to develop or change their approved drug lists, which could potentially improve or restrict access to MS medications for people living with MS. To ensure that […]

Read News Article

Experimental SPMS Medication Shows Positive Results

A Phase III study with siponimod, an experimental oral treatment for MS, is showing positive results for individuals with secondary-progressive multiple sclerosis (SPMS). According to an August 25th press release from Novartis, the pharmaceutical company developing siponimod, the Phase III EXPAND study met its primary endpoint, which was to reduce the risk of confirmed disability […]

Read News Article

The Multiple Sclerosis Association of America Launches Online Support Community for Individuals Affected by MS

The Multiple Sclerosis Association of America (MSAA) announces the official launch of My MSAA Community. Powered by HealthUnlocked, this new online community forum has been created to offer people living with multiple sclerosis (MS), care partners, and family members a way to connect with others going through the same challenges as well as receive valuable […]

Read News Article

Highlights from the AAN and CMSC Annual Meetings

Two vital conferences providing the latest information and research on multiple sclerosis (MS) take place in the spring of each year. These are the American Academy of Neurology (AAN) and The Consortium of Multiple Sclerosis Centers (CMSC) Annual Meetings. The 68th Annual Meeting of the AAN took place April 15-21, 2016, in Vancouver, Canada. More […]

Read News Article

My MS Manager Named One of the Best MS Apps of 2016

My MS Manager™, MSAA’s free mobile phone app, has been recognized by Healthline.com as one of the best multiple sclerosis (MS) apps for the fourth consecutive year. Healthline editors selected this year’s winners based on user ratings, frequent updates, and overall impact in making a valuable contribution to the lives of people in the MS […]

Read News Article

FDA Accepts Review of Application for Ocrelizumab

On June 27, 2016, Genentech, a member of the Roche group, announced that the Biologics License Application (BLA) for ocrelizumab has been accepted for review by the United States Food and Drug Administration (FDA). This is the first time that an investigational medication is being reviewed for the treatment of two types of multiple sclerosis […]

Read News Article